Abstract YO39
Case summary
Background: Follicular thyroid carcinoma commonly presents with hematogenous metastasis to the lung and bone and rarely to the kidney. We report a case of a 61-year old woman with a metastatic follicular thyroid carcinoma to the kidney. This case report shows how a systematic approach on a patient with a renal mass can lead to a diagnosis of an unexpected primary cancer.
Case Report: A 61-year old female presented with progressively enlarging back mass. Whole abdominal ultrasound revealed right renal mass; chest CT scan showed multiple heterogeneously varisized pulmonary nodules. Ct-guided fine needle aspiration biopsy of the lung nodule was compatible with a non-small cell carcinoma. Immuno-histochemistry was positive for CK7, TTF1 and thyroglobulin and CK 20 negative favoring metastatic thyroid carcinoma. Ultrasound-guided core needle biopsy of the renal mass was compatible with thyroid carcinoma, metastatic (thyroglobulin positive). The final histopathology report after thyroidectomy was non-invasive follicular thyroid neoplasm with papillary-like nuclear features. The patient received radioactive iodine and is now with better quality of life.
Discussion: Metastatic follicular thyroid carcinoma is a rare phenomenon with only 25 cases reported in the English literature to date. Johnson et al in 1982 reported a case of follicular thyroid carcinoma with metastasis to the kidney 37 years after resection of the primary tumor. In a study by Parameswaran in 2016 on patterns of metastasis in follicular thyroid carcinoma, they found out that 40% of cases metastasized at a median of 4.5 years after initial thyroidectomy, lungs being the most common site followed by bone (25%), regional lymph nodes (13%) and brain (12%). None of the said cohort had metastasis to the kidney. The best management of FTC presenting as metastatic disease should be managed aggressively with total thyroidectomy followed by RAI which was done in our patient.
Conclusion: Given the rarity of thyroid metastasis to the kidney, a diagnostic dilemma for this case was a challenge. This case provides new data to clinicians that thyroid carcinoma can metastasize to the kidney and may mimic renal cell carcinoma although rarely reported.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract